Zola, H.Beare, A.2009-11-202009-11-202008Current Opinion in Molecular Therapeutics, 2008; 10(1):68-741464-84312040-3445http://hdl.handle.net/2440/53599GPC Biotech AG is developing 1D09C3, an anti-MHC class II (HLA-DR) fully human IgG4 antibody isolated by MorphoSys AG (from its HuCAL library of human antibodies), for the potential treatment of hematological malignancies. In December 2006, positive safety data from two phase I clinical trials were reported. Final phase I data were expected in mid-2007; however, no additional data have been released at the time of publication.enAnimalsHumansAntibodies, MonoclonalHistocompatibility Antigens Class IIDrug Evaluation, PreclinicalAntibody SpecificityStructure-Activity RelationshipClinical Trials as TopicPatents as TopicAntibodies, Monoclonal, HumanizedContraindicationsJournal article00200800930002526974000092-s2.0-3864908316543894